StockNews.AI
ORN
StockNews.AI
218 days

79,345 Orion Corporation A shares converted into B shares

1. 79,345 A shares converted to B shares, maintaining total shares at 141 million. 2. Post-conversion, the share voting rights total 763 million votes. 3. Orion's 2023 net sales reached EUR 1,190 million. 4. The company focuses on oncology and pain in its R&D. 5. Orion operates globally, providing human and veterinary pharmaceuticals.

3m saved
Insight
Article

FAQ

Why Neutral?

Share conversion is administrative; minimal direct market effects observed previously.

How important is it?

While significant to share structure, it doesn't immediately affect financial performance.

Why No Impact?

Share structure change unlikely to lead to immediate stock price fluctuations.

Related Companies

ORNBHORNAH
January 13, 2025 02:50 ET  | Source: Orion Oyj ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE13 JANUARY 2025 at 9.50 EET                   79,345 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 79,345 A shares have been converted into 79,345 B shares. The conversion has been entered into the Trade Register on 13 January 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,752,263 A shares and 108,382,015 B shares. The number of votes of the company's shares is after the conversion 763,427,275. Orion Corporation René LindellCFO   Olli HuotariSVP, Corporate Functions                                                Contact person:Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721   Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Related News